Orchard Therapeutics PLC
Chris Davis has a diverse work experience that spans from directing their own cafe to working in pharmaceutical companies like GSK, Senzer Limited, and Orchard Therapeutics. Their roles have included positions as a Director, Process Development Engineer, Investigator, and Principal Scientist, focusing on process engineering, project management, and research in biopharmaceutical process development.
Chris Davis pursued their education in a chronological order starting with A-Levels at Cadbury Sixth Form College from 2002 to 2004, with a focus on subjects like Maths, Physics, History, Government & Politics, and Further Maths AS. Chris then continued their studies at the University of Bath from 2005 to 2010, where they obtained a Master of Engineering (MEng) in Mechanical Engineering. Subsequently, they attended Newcastle University from 2011 to 2015, where they completed an EngD in Biopharmaceutical Process Development within the field of Chemical Engineering. Moreover, in 2021, Chris obtained a certification in Process Scale-up, Validation, and Technology Transfer for Biologics from Symmetric Training.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.